for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oncternal Therapeutics Inc

ONCT.PH

Latest Trade

5.93USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.77

 - 

7.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.93
Open
--
Volume
--
3M AVG Volume
0.56
Today's High
--
Today's Low
--
52 Week High
7.69
52 Week Low
0.77
Shares Out (MIL)
15.38
Market Cap (MIL)
65.54
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Oncternal Reports Qtrly Loss Per Share $3.38

Gtx Inc Says Entered Amendment To Agreement & Plan Of Merger & Reorganization With Oncternal Therapeutics & Grizzly Merger Sub

GTx, Oncternal Therapeutics Enter Merger Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Industry

Biotechnology & Drugs

Contact Info

12230 El Camino Real Ste 300

+1.858.4341113

http://www.oncternal.com/

Executive Leadership

James B. Breitmeyer

President, Chief Executive Officer

Richard G. Vincent

Chief Financial Officer

Gunnar F Kaufmann

Chief Scientific Officer

Hazel M. Aker

General Counsel

Igor P. Bilinsky

Chief Business Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
57.29
Price To Book (MRQ)
2.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-127.14
Return on Equity (TTM)
-101.72

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up